知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.204 秒)

    Therapeutic uses of kallikreins
    62.
    发明申请
    Therapeutic uses of kallikreins 审中-公开
    激肽释放酶的治疗用途

    公开(公告)号：US20060287231A1

    公开(公告)日：2006-12-21

    申请号：US11436059

    申请日：2006-05-18

    申请人： Chee-Wui Chu ,  ZhongQi Shao ,  Quan Yang ,  Genevieve Huppe

    发明人： Chee-Wui Chu ,  ZhongQi Shao ,  Quan Yang ,  Genevieve Huppe

    IPC分类号： A61K38/17

    CPC分类号： A61K38/4853

    摘要： The present invention relates to therapeutic applications of kallikreins and compositions containing them for treating, preventing and/or ameliorating cancers, especially epithelial cancers, such as ovarian, breast and cervical cancer.

    摘要翻译： 本发明涉及激肽释放酶及其组合物的治疗应用，用于治疗，预防和/或改善癌症，特别是卵巢癌，乳腺癌和子宫颈癌等上皮癌。

    Method and product for locating an internal bleeding site
    63.
    发明申请
    Method and product for locating an internal bleeding site 审中-公开
    用于定位内部出血部位的方法和产品

    公开(公告)号：US20060024229A1

    公开(公告)日：2006-02-02

    申请号：US10903303

    申请日：2004-07-29

    申请人： Seth Karp ,  Evan Garfein

    发明人： Seth Karp ,  Evan Garfein

    IPC分类号： A61K51/00 ,  A61K38/48 ,  A61K38/36 ,  A61K35/14

    CPC分类号： A61K38/363 ,  A61K38/36 ,  A61K38/37 ,  A61K38/4846 ,  A61K38/4853 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/0034 ,  A61K49/0056 ,  A61K49/14 ,  A61K51/08 ,  B82Y5/00 ,  B82Y10/00

    摘要： A method is provided for localizing an internal bleeding site whereby a protein or other factor involved in the clotting process is complexed to an imaging agent and injected into a patient believed to be at risk of internal bleeding. A clot in the patient will naturally accumulate a certain concentration of the injected complex, and within a short period of time the concentration becomes sufficient to be detected by an imaging apparatus. The imaging contrast agent may, for example, be an MRI contrast agent, a CT contrast agent, a PET agent, or a fluorescent substance.

    摘要翻译： 提供了一种用于定位内部出血部位的方法，由此参与凝血过程的蛋白质或其它因子与成像剂复合并注射到被认为具有内部出血风险的患者中。 患者中的凝块将自然地积聚注射的复合物的一定浓度，并且在短时间内浓度变得足以由成像装置检测。 成像造影剂可以是例如MRI造影剂，CT造影剂，PET剂或荧光物质。

    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
    64.
    发明申请
    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases 审中-公开
    用丝氨酸蛋白酶抑制内皮细胞增殖和调节血管生成的组合物和方法

    公开(公告)号：US20040253226A1

    公开(公告)日：2004-12-16

    申请号：US10777998

    申请日：2004-02-12

    发明人： John W. Holaday ,  Anne H. Fortier

    IPC分类号： A61K038/48

    CPC分类号： A61K38/4853 ,  A61K2300/00

    摘要： Compositions and methods for regulating angiogenic activity wherein the compositions comprise serine proteases including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

    摘要翻译： 用于调节血管生成活性的组合物和方法，其中组合物包含丝氨酸蛋白酶，包括激肽释放酶例如前列腺特异性抗原（PSA），丝氨酸蛋白酶同系物或其活性片段。 丝氨酸蛋白酶和激肽释放酶对人和其他动物细胞，特别是内皮细胞表现出有力的抗​​血管生成活性。 更具体地，PSA，PSA同系物及其抑制片段可以与药学上可接受的赋形剂或载体组合，并用于抑制血管发生和血管生成相关疾病如癌症，关节炎，黄斑变性和糖尿病性视网膜病变。

    Therapeutic uses of glandular kallikrein
    65.
    发明申请
    Therapeutic uses of glandular kallikrein 失效
    腺体激肽释放酶的治疗用途

    公开(公告)号：US20030216306A1

    公开(公告)日：2003-11-20

    申请号：US10162697

    申请日：2002-06-06

    发明人： Edris Sabbadini ,  Eva Nagy ,  Istvan Berczi

    IPC分类号： A61K048/00 ,  A61K038/17 ,  C12N015/85

    CPC分类号： A61K39/0013 ,  A61K38/4853 ,  A61K39/0008 ,  A61K39/39 ,  A61K2039/55516 ,  Y10S514/825 ,  A61K2300/00

    摘要： An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for the induction of oral tolerance and that K1 is involved in mediating this function.

    摘要翻译： 从大鼠下颌腺（SMG *）分离的40kDa分子量的免疫抑制肽具有抑制肠胃外给予大鼠和小鼠的免疫反应的能力。 通过部分测序和酶活性将肽鉴定为腺激肽释放酶（K1）。 进一步的实验表明，从Lewis大鼠切除SMG（SMGx）可防止口服诱导对天然牛II型胶原蛋白（BCII）的免疫耐受性。 因此，当SMGx大鼠给予口服BCII并随后用相同的抗原免疫时，发展出胶原诱导的关节炎（CA），而给予相同治疗的正常大鼠被保护免于该疾病。 当口服MCGx大鼠与BCII联合使用猪K1时，这种动物开发口服耐受能力得到充分恢复。 这些结果表明，诱导口服耐受需要正常的SMG功能，K1参与介导该功能。

    Method of treating cancer
    66.
    发明申请
    Method of treating cancer 审中-公开
    癌症治疗方法

    公开(公告)号：US20030215456A1

    公开(公告)日：2003-11-20

    申请号：US09969322

    申请日：2001-10-02

    发明人： Sui-Long Yao ,  Raymond E. Jones ,  Deborah DeFeo-Jones ,  David C. Heimbrook ,  Patricia Rhymer ,  Pamela J. Wasserbly

    IPC分类号： A61K039/00 ,  A61K038/14

    CPC分类号： C07K7/06 ,  A61K38/4853 ,  C07K14/47 ,  A61K2300/00

    摘要： The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a tachykinin receptor antagonist, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a tachykinin receptor antagonist. The invention also relates to methods of preparing such compositions.

    摘要翻译： 本发明涉及使用PSA缀合物的化合物和速激肽受体拮抗剂的组合来治疗癌症的方法，所述方法包括以任何顺序或同时向所述哺乳动物施用至少两种治疗剂的量 来自由PSA缀合物的化合物和速激肽受体拮抗剂组成的组。 本发明还涉及制备这种组合物的方法。

    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
    67.
    发明申请
    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers 失效

    公开(公告)号：US20020137668A1

    公开(公告)日：2002-09-26

    申请号：US09907402

    申请日：2001-07-17

    发明人： John W. Holaday ,  Anne H. Fortier

    IPC分类号： A01N037/18

    CPC分类号： A61K38/4853 ,  A61K2300/00

    摘要： Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
    68.
    发明授权
    Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers 失效
    使用癌症标记物抑制内皮细胞增殖和调节血管生成的组合物和方法

    公开(公告)号：US06413513B1

    公开(公告)日：2002-07-02

    申请号：US09413049

    申请日：1999-10-06

    申请人： John W. Holaday ,  Anne H. Fortier

    发明人： John W. Holaday ,  Anne H. Fortier

    IPC分类号： A61K39395

    CPC分类号： A61K38/4853 ,  A61K2300/00

    摘要： Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins exhibit potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically acceptable excipient or carrier and used to inhibit angiogenesis and angiogenesis-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

    摘要翻译： 用于调节血管生成活性的组合物和方法，其中组合物包含癌标记物，包括激肽释放酶例如前列腺特异性抗原（PSA），丝氨酸蛋白酶同系物或其活性片段。 丝氨酸蛋白酶和激肽释放酶对人和其他动物细胞，特别是内皮细胞表现出有力的抗​​血管生成活性。 更具体地，PSA，PSA同系物及其抑制片段可以与药学上可接受的赋形剂或载体组合，并用于抑制血管发生和血管生成相关疾病如癌症，关节炎，黄斑变性和糖尿病性视网膜病变。